CJC-1295 With DAC is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC), a maleimide group that binds serum albumin to extend circulating half-life. For research teams studying the somatotropic axis, the DAC modification provides a long-acting GHRH-receptor tool for time-dependent signaling studies. Puritide Research supplies CJC-1295 With DAC as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›CJC-1295 With DAC 5 mg Vial
Product Specifications
- Application
- GHRH-receptor signaling research (long-acting albumin-binding GHRH analog)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- C165H269N47O46
- CAS Number
- 446262-90-4
- Molecular Weight
- ~3647.2 g/mol
- Synonyms
- CJC-1295 DAC, CJC-1295 with Drug Affinity Complex, DAC:GRF, GRF (1-29) drug affinity complex, long-acting GHRH analog
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is CJC-1295 With DAC?
CJC-1295 With DAC is a synthetic analog of the biologically active GHRH (1-29) fragment, carrying stabilizing amino acid substitutions plus a Drug Affinity Complex. The DAC is a maleimidopropionyl group appended to the peptide that forms a covalent bond with circulating serum albumin, greatly extending the molecule's presence in solution.
This albumin-binding feature distinguishes it from the No-DAC variant. In research settings, the DAC form is studied as a long-acting GHRH-receptor agonist, making it useful for investigating sustained receptor engagement and prolonged signaling profiles that the shorter-acting form cannot model.
Present understanding derives from in vitro assays, animal models, and human research on GHRH analogs. Findings should be interpreted within their experimental context and not treated as established clinical outcomes. Puritide Research supplies CJC-1295 With DAC strictly for laboratory use; it is not approved for human or veterinary application.
CJC-1295 With DAC Mechanism of Action (Research Only)
CJC-1295 With DAC is studied as a long-acting GHRH-receptor agonist used to investigate sustained signaling in somatotroph cells. The mechanisms below reflect observations from biochemical assays, cell-culture studies, and animal models, and should be read strictly in a research context.
Albumin Binding via the Drug Affinity Complex
The defining structural feature is the Drug Affinity Complex, a maleimide group that reacts with a cysteine thiol on serum albumin to form a reversible covalent bond. In experimental systems this albumin conjugation is associated with markedly prolonged molecular persistence and sustained receptor engagement, making the compound a model for studies of time-dependent GHRH-receptor signaling.
GHRH-Receptor Signaling
As a GHRH (1-29) analog, CJC-1295 With DAC is investigated for its interaction with the GHRH receptor on pituitary somatotroph cells, where engagement is associated with cAMP-dependent signaling and growth hormone release. Because of its extended duration, the DAC form is studied for sustained rather than pulsatile signaling profiles.
This makes it a complementary research tool to the No-DAC variant: investigators use the two forms within the same framework to contrast prolonged versus short-acting GHRH-receptor stimulation and their respective downstream signaling dynamics.
CJC-1295 With DAC Research Applications
CJC-1295 With DAC is investigated across preclinical studies as a long-acting GHRH-receptor tool for exploring sustained somatotropic-axis signaling. The observations below derive from biochemical studies, cell-based assays, and animal models, and should be interpreted within their respective settings.
Sustained GHRH Signaling Studies
A primary application is investigating prolonged GHRH-receptor engagement and its downstream signaling and IGF-related responses in animal and cell models. Its extended duration makes it suited to studies requiring sustained receptor occupancy over time.
The compound is also used in research on the pharmacological consequences of albumin-binding half-life extension, using the DAC strategy as a model for studying how molecular persistence influences receptor signaling behavior.
Comparative & Endocrine Models
Researchers use CJC-1295 With DAC in comparative studies contrasting long-acting and short-acting GHRH analogs, characterizing differences in signaling duration and stability across the somatotropic axis. These studies aim to improve understanding of GHRH-receptor pharmacology rather than to establish physiological or therapeutic effects.
Comparison
| Parameter | CJC-1295 With DAC | CJC-1295 No DAC | Ipamorelin |
|---|
| Molecular classification | GHRH (1-29) analog with DAC | GHRH (1-29) analog | Synthetic pentapeptide GHS |
| Primary receptor target | GHRH receptor | GHRH receptor | Ghrelin / GHS receptor |
| Albumin-binding DAC group | Present | Absent | Absent |
| Studied duration profile | Long-acting | Short-acting | Short-acting |
| Primary research focus | Sustained GHRH signaling | Pulsatile GHRH signaling | Selective GHS signaling |
Laboratory Safety & Handling (Research Use Only)
CJC-1295 With DAC is a synthetic, lyophilized research peptide for laboratory investigation only. It should be handled by qualified personnel in controlled environments, in accordance with institutional policies, laboratory safety procedures, and applicable regulations. As a research material, laboratories should implement practices that prioritize material integrity, traceability, and reproducibility.
Handling & Storage Guidelines
Follow institutional SOPs, chemical hygiene plans, and approved protocols; wear appropriate PPE (lab coat, gloves, eye protection); and use engineering controls where required. Record lot numbers, storage conditions, and handling activities, and retain Certificates of Analysis and batch documentation to support traceability and audit readiness.
Store material under the conditions specified in product documentation, protected from excessive heat, moisture, and direct light. Reconstituted peptide should be kept refrigerated and used within the timeframe indicated by your protocol. Consistent handling and documentation support reliable, reproducible outcomes.
Certificate of Analysis & Quality Assurance
Each CJC-1295 With DAC batch ships with a third-party-verified Certificate of Analysis, providing transparent, research-grade quality control. The CoA includes a purity assessment (HPLC / reverse-phase chromatography), mass-spectrometry identity confirmation, and lot number, testing date, and method documentation.
Researchers may request sample CoAs (PDF) ahead of purchase to confirm testing parameters, analytical methods, and batch consistency, and are encouraged to perform independent verification.
Research Use Only
